Real-world data to combat COVID-19

• Monitoring data on hospitals’ utilisation and capacity rates: location and number of licensed beds, staffed beds, ICU beds, and total bed utilisation rates
• Plan for critical care based on epidemiological data on COVID-19 and clinical outcomes: modelling tools development to identify surges in clinical demand, as well as best- and worst-case scenarios of COVID-19-induced strain on hospital capacity
• High-risk patient identification: respiratory issues, social isolation, exposure risk survey (recent travel, attendance at large public events, symptoms of the virus), patient data collection to better understand risk factors (genetic, clinical, and environmental data), COVID-19 impact on certain communities assessment
• Modelling framework for different types, intensities, and durations of interventions to be implemented and evaluation of the effect on the spread of the virus over time

Click here to learn more

About SVMPharma

SVMPharma is an innovative strategic consultancy, specialising in Real-World Evidence (RWE) for the pharmaceutical industry. SVMPharma generates RWE within UK and Europe through bespoke online Real-World Treatment Evaluators, leading to successful health technology appraisal (HTA) submissions. Clinical trial programmes do not reflect real-world clinical practice and outcomes, RWE supplements and enhances clinical datasets. SVMPharma’s specialist teams focus on delivering the outcomes that matter to your brand.

For more information, please visit www.svmpharma.com and contact us at enquiry@svmpharma.com

ref: JUN2020DC001